CL
NBIX icon

CSS LLC’s Neurocrine Biosciences NBIX Stock Holding History

CSS LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Sell
6,350
-600
-9% -$89K 0.04% 326
2026
Q1 		$916K Buy
6,950
+5,330
+329% +$707K 0.04% 365
2025
Q4 		$230K Buy
+1,620
New +$235K 0.01% 742
2025
Q2 		– Sell
-2,720
Closed -$301K – 1084
2025
Q1 		$301K Buy
+2,720
New +$345K 0.02% 632

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CSS LLC's NBIX Position: Q2 2026 in Review

CSS LLC reduced its Neurocrine Biosciences (NBIX) stake by 8.6% in Q2 2026, selling an estimated $89K and leaving 6,350 shares worth $1.07M. The position accounts for 0.04% of the portfolio, ranked #326.

CSS LLC first reported a position in NBIX in Q1 2025 and has held it in 4 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • CSS LLC held 6,350 shares of Neurocrine Biosciences worth $1.07M as of Q2 2026.
  • CSS LLC sold 600 Neurocrine Biosciences shares in Q2 2026, an estimated $89K.
  • Neurocrine Biosciences made up 0.04% of CSS LLC's portfolio in Q2 2026, its #326 holding.
  • CSS LLC first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 4 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on CSS LLC's 13F filing for Q2 2026, filed 14 Aug 2026.